Eli Lilly lifts 2019 profit forecast after third-quarter beat

This post was originally published on this site


(Reuters) – Eli Lilly and Co (N:) reported a 9.1% increase in third-quarter profit on Wednesday, helped by higher sales of its top-selling diabetes drug, Trulicity, and lower tax expense.

Net income rose to $1.25 billion, or $1.37 per share, in the quarter ended Sept. 30, from $1.15 billion, or $1.12 per share, a year earlier.

Revenue rose 3.2% to $5.48 billion.   

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Add Comment